New quarterly report expected Apr 29, 2026. Report will refresh after results.
A
AbbVie Inc.
ABBV · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
HUMIRA's Ghost Is Gone, But SKYRIZI Is Already Too Big
Most investors are celebrating AbbVie's HUMIRA transition as a solved problem — the real question is whether management has enough pipeline depth to avoid rebuilding the same cliff at a higher elevation, and the voluntary Trump administration pricing agreement may have bought a decade of regulatory peace that the market is not yet pricing in.
Flowly Score
Apr 16 Close
+101%$208.89
Fair Value
$420.00
68
Strongat $208.89
Business Strengthmoderate
AbbVie executed the rare feat of engineering a successor franchise before the predecessor collapsed, but concentration risk has simply migrated upward — SKYRIZI is becoming the new single point of failure at higher altitude. The Botox franchise is the quiet gem: a consumer brand masquerading as a drug, immune to biosimilars and payer politics in ways no biologic ever will be.
Financial Resiliencemoderate
The cash engine is exceptional — nearly $18B in annual FCF from a business that barely touches capital expenditure — but sitting atop nearly $69B in debt with an Altman Z score in the gray zone means the balance sheet is doing real work just to stay neutral. The Piotroski 8/9 confirms operating quality; the leverage load is the honest counterweight.
Growth & Trajectorystrong
SKYRIZI and RINVOQ combined already surpassed the 2027 guidance targets set just two years ago — that is not a company sandbagging, that is a product cycle running hotter than even bulls expected. The neuroscience buildout (migraine, Parkinson's, psychiatry pipeline) gives AbbVie a genuine third act in early formation, which changes the terminal growth equation if any of it converts.
Valuationstrong
The headline P/E is almost completely fictional — an accounting illusion produced by amortizing a massive acquisition through the income statement — and investors who anchor to it are mispricing the business. At an EV/EBITDA below its five-year average, with a FCF yield near the highest it has been since the Allergan deal closed, the market is essentially offering access to a best-in-class immunology franchise at a price that prices in no third act whatsoever.
Riskmoderate
The IRA is not a vague regulatory headwind — it is a direct mechanism that could force Medicare price negotiation on SKYRIZI specifically, the drug holding the entire valuation together. RINVOQ's black box warning, GLP-1-driven demand compression in inflammatory disease, and the combined CEO/Chairman governance structure are compounding risks that do not show up in any single quarter's results but can reprice the stock abruptly when they do.
AbbVie is a textbook case of price rescuing a complicated story. The business quality is genuinely high — best-in-class immunology drugs with expanding indication footprints, a biosimilar-proof aesthetics franchise that operates like a luxury consumer brand, and a cash generation engine so powerful it embarrasses its own reported earnings. The amortization drag obscures the true economic picture: what looks like a 96x earnings multiple resolves, at the cash flow level, to something far more rational. The EV/EBITDA entry point reflects a business in a mid-cycle transition, not a peak. A management team that launched SKYRIZI trials while HUMIRA was still printing record revenues has demonstrated it can think past the current quarter — that cultural trait has compounding value. The trajectory from here depends on whether the neuroscience buildout converts. Migraine and Parkinson's are not core immunology, which means AbbVie is attempting to become a multi-franchise specialty pharma rather than a one-trick immunology giant — that is the right strategic direction, but execution risk in therapeutic category expansion is real and historically underestimated. The $8B deployed across 30+ business development deals over two years signals urgency, not desperation, and the CAR-T and next-generation psychiatry assets give the pipeline a probability distribution that is wider than the base case suggests. If even one of those converts at scale, the terminal growth rate assumption in every model needs to move up. The single biggest concrete risk is SKYRIZI getting selected for Medicare price negotiation under the IRA. This is not abstract — SKYRIZI is already a top-five drug globally by revenue and accelerating, which is precisely the profile that lands a drug on the negotiation list. If that happens before 2030, every growth projection bends sharply lower, the debt burden that currently looks manageable becomes uncomfortable, and the valuation case built on sustained FCF growth requires a complete rebuild. The voluntary pricing agreement with the current administration buys time, but administrations change and agreements lapse — this risk does not disappear, it defers.